Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

NICE cancer guidance: good news for Ibrance and Lynparza

The UK’s pricing regulator NICE decides whether new therapies are sufficiently cost-effective for NHS use. In its most recent publishing of guidance, NICE determined two oncology drugs – Pfizer’s Ibrance and AstraZeneca’s Lynparza – were promising, but for certain patient populations they should only be available through its managed-access scheme while further data is gathered. What explains this decision?

Close
Close
Close

Go Top